Viatris (VTRS) Cash from Investing Activities (2019 - 2026)
Viatris (VTRS) posted quarterly Cash from Investing Activities of $277.4 million for Q1 2026, up 526.11% year-over-year from $44.3 million in Q1 2025, and up 231.34% quarter-over-quarter from -$211.2 million in Q4 2025.
Viatris (VTRS) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Viatris' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $277.4 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 526.11% year-over-year to $277.4 million; the TTM figure through Mar 2026 stood at -$85.2 million (down 104.51% YoY), while the FY2025 annual figure was -$427.7 million, down 123.75% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $277.4 million, up from -$211.2 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $1.7 billion in Q3 2024, with the low at -$749.5 million in Q1 2023.
- The 5-year median for Cash from Investing Activities is -$66.9 million (2022), against an average of $132.9 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities plunged 1020.33% in 2023, then surged 3283.79% in 2024.
- Viatris' Cash from Investing Activities stood at $1.7 billion in 2022, then plunged by 98.46% to $26.7 million in 2023, then slumped by 731.84% to -$168.7 million in 2024, then declined by 25.19% to -$211.2 million in 2025, then jumped by 231.34% to $277.4 million in 2026.
- Business Quant data shows VTRS's Cash from Investing Activities at $277.4 million in Q1 2026, -$211.2 million in Q4 2025, and -$98.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | -2.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.60 Mn |
| Jun 30, 2026 | -51.60 Mn |
| Mar 31, 2026 | 277.40 Mn |
| Mar 31, 2026 | 277.40 Mn |
| Dec 31, 2025 | -211.20 Mn |
| Dec 31, 2025 | -211.20 Mn |
| Sep 30, 2025 | -98.90 Mn |
| Sep 30, 2025 | -98.90 Mn |
| Jun 30, 2025 | -52.50 Mn |
| Jun 30, 2025 | -52.50 Mn |
| Mar 31, 2025 | -65.10 Mn |
| Mar 31, 2025 | -65.10 Mn |
| Dec 31, 2024 | -168.70 Mn |
| Dec 31, 2024 | -168.70 Mn |
| Sep 30, 2024 | 1.75 Bn |
| Sep 30, 2024 | 1.75 Bn |
| Jun 30, 2024 | 375.80 Mn |
| Jun 30, 2024 | 375.80 Mn |
| Mar 31, 2024 | -154.30 Mn |
| Mar 31, 2024 | -154.30 Mn |